New COVID-19 Vaccine Codes: October Update
Date Posted: Monday,
November 01, 2021
Recently, new Current Procedural Terminology (CPT®) codes for a ready-to-use vaccine product (tris-sucrose formulation) from Pfizer and its administration were added to previously established vaccine codes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]).
The CPT Editorial Panel (the Panel) has approved a new vaccine product code and its associated administration codes of the reformulated Pfizer vaccine product for pediatric use. This reformulated vaccine product involves the administration of two intramuscular injections of a diluted and reconstituted dosage of 10 mcg/0.2 mL volume of the tris-sucrose formula, which is administered 21 days apart, for use in patients ages 5 through 11 years of age. As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit.
In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes) that features timely updates of the Panel's actions. The last COVID-19 update was in the CPT® Assistant Special Edition: September Update (2021) in which the Pfizer and Moderna third-dose vaccine administration codes (0003A, 0013A); Pfizer's ready-to-use vaccine product code (91305) and its associated administration codes (0051A, 0052A, 0053A); Moderna's lower-dose vaccine product code (91306) and associated booster-dose administration code (0064A); and booster-dose administration codes for the Pfizer vaccine product (0004A, 0054A) were established.
This issue of CPT® Assistant Special Edition introduces and provides guidance on the appropriate use of the new pediatric Pfizer vaccine product code (91307) for use in patients ages 5 through 11 years of age and its associated new administration codes (0071A, 0072A).
- 0001A
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose - I0002A
Second dose - I0003A
Third dose - I0004A
Booster dose
(Report 0001A, 0002A, 0003A, 0004A for the administration of vaccine 91300. Do not report 0001A, 0002A, 0003A, 0004A in conjunction with 91305, 91307.)
- I0051A
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose - I0052A
Second dose - I0053A
Third dose - I0054A
Booster dose
(Report 0051A, 0052A, 0053A, 0054A for the administration of vaccine 91305. Do not report 0051A, 0052A, 0053A, 0054A in conjunction with 91300, 91307.)
- I0071A
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose - I0072A
Second dose
(Report 0071A, 0072A for the administration of vaccine 91307. Do not report 0071A, 0072A in conjunction with 91300, 91305.)
Vaccines, Toxoids
- I91300
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use
(Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A. Do not report 91300 in conjunction with administration codes 0051A, 0052A, 0053A, 0054A, 0071A, 0072A.) - I91305
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
(Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A. Do not report 91305 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0071A, 0072A.) - I91307
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
(Report 91307 with administration codes 0071A, 0072A. Do not report 91307 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A.)
